Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) has been given an average recommendation of “Hold” by the six research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $25.00.
Separately, HC Wainwright boosted their target price on Revance Therapeutics from $20.00 to $25.00 in a research report on Wednesday.
Revance Therapeutics Price Performance
RVNC opened at $22.49 on Wednesday. The stock has a 50-day moving average price of $15.31 and a 200-day moving average price of $15.57. The company has a debt-to-equity ratio of 14.80, a current ratio of 4.01 and a quick ratio of 3.87. The firm has a market cap of $1.64 billion, a PE ratio of -5.84 and a beta of 1.03. Revance Therapeutics has a 1 year low of $11.27 and a 1 year high of $30.00.
Revance Therapeutics (NASDAQ:RVNC – Get Rating) last issued its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.03). Revance Therapeutics had a negative return on equity of 368.74% and a negative net margin of 265.04%. The business had revenue of $25.26 million during the quarter, compared to analysts’ expectations of $23.55 million. Sell-side analysts predict that Revance Therapeutics will post -3.97 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Revance Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Palo Alto Investors LP increased its position in shares of Revance Therapeutics by 1.1% during the 1st quarter. Palo Alto Investors LP now owns 4,415,689 shares of the biopharmaceutical company’s stock valued at $86,106,000 after purchasing an additional 46,323 shares during the last quarter. Capital World Investors grew its stake in shares of Revance Therapeutics by 25.1% during the 4th quarter. Capital World Investors now owns 3,712,000 shares of the biopharmaceutical company’s stock valued at $60,580,000 after acquiring an additional 745,000 shares during the period. Vanguard Group Inc. grew its stake in shares of Revance Therapeutics by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 3,645,311 shares of the biopharmaceutical company’s stock valued at $71,084,000 after acquiring an additional 43,014 shares during the period. Polar Capital Holdings Plc grew its stake in shares of Revance Therapeutics by 8.7% during the 1st quarter. Polar Capital Holdings Plc now owns 2,456,497 shares of the biopharmaceutical company’s stock valued at $47,902,000 after acquiring an additional 196,797 shares during the period. Finally, Jennison Associates LLC grew its stake in shares of Revance Therapeutics by 10.8% during the 1st quarter. Jennison Associates LLC now owns 2,441,286 shares of the biopharmaceutical company’s stock valued at $47,605,000 after acquiring an additional 237,722 shares during the period. Hedge funds and other institutional investors own 79.94% of the company’s stock.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
Receive News & Ratings for Revance Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Revance Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.